Latest Conference Articles

September 13th 2019, 8:21pm

Society of Hematologic Oncology Annual Meeting (SOHO)

David G. Maloney, MD, PhD, discusses the initiative to use the Center for International Blood and Marrow Transplant Research Cellular Therapy Registry to report real world experience of tisagenlecleucel CAR T cells targeting CD19 in patients with acute lymphoblastic leukemia.

September 13th 2019, 5:23pm

IASLC World Conference on Lung Cancer

Liposomal irinotecan achieved disease control in almost half of patients as a second-line treatment for small cell lung cancer, according to findings from Part 1 of the phase II/III RESILIENT trial presented at the 2019 World Conference on Lung Cancer.

September 13th 2019, 2:46am

Society of Hematologic Oncology Annual Meeting (SOHO)

Ruben Mesa, MD, discusses the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.

September 13th 2019, 2:32am

Society of Hematologic Oncology Annual Meeting (SOHO)

Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.

September 13th 2019, 2:26am

Society of Hematologic Oncology Annual Meeting (SOHO)

Partow Kebriaei, MD, discusses the eligibility criteria necessary for patients with acute lymphocytic leukemia to undergo stem cell transplantation.

September 13th 2019, 1:57am

Society of Hematologic Oncology Annual Meeting (SOHO)

Novel strategies are needed to enhance the efficacy of CAR T-cell therapies in patients with acute lymphoblastic leukemia, including new constructs that target more than 1 antigen.

September 12th 2019, 8:54pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Reducing or interrupting duvelisib treatment does not increase toxicity or reduce outcomes with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Furthermore, treatment with the PI3K inhibitor led to a superior median progression-free survival compared with ofatumumab while producing rapid and durable responses in heavily pretreated patients.

September 11th 2019, 1:56am

IASLC World Conference on Lung Cancer

Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer patients who were treated with brigatinib versus crizotinib.

September 11th 2019, 1:37am

IASLC World Conference on Lung Cancer

David Carbone, MD, PhD, director, James Thoracic Center, Ohio State University Comprehensive Cancer Center, discusses two abstracts on immunotherapy that were presented by colleagues at the 2019 World Conference on Lung Cancer in Barcelona, Spain.

September 11th 2019, 1:27am

IASLC World Conference on Lung Cancer

Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics, and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non-small cell lung cancer.

September 11th 2019, 1:02am

IASLC World Conference on Lung Cancer

Targeted therapies for non­–small cell lung cancer produced mixed results in a novel multiarm clinical trial that matched tumor mutations to drugs targeting the mutations.

September 10th 2019, 9:31pm

IASLC World Conference on Lung Cancer

The addition of atezolizumab (Tecentriq) to carboplatin and nab-paclitaxel (Abraxane) showed a clinical overall survival benefit among a subgroup of patients with advanced squamous non–small cell lung cancer.

September 10th 2019, 7:25pm

IASLC World Conference on Lung Cancer

Treatment with nivolumab (Opdivo) was associated with a 5-year overall survival rate of 13.4% compared with 2.6% with docetaxel in patients with previously treated non–small cell lung cancer.

September 10th 2019, 1:46am

IASLC World Conference on Lung Cancer

Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers.

September 10th 2019, 1:45am

IASLC World Conference on Lung Cancer

Corey J. Langer, MD, director, thoracic oncology, Penn Medicine, discusses the future of immunotherapy during a discussion about KEYNOTE-021 at the 2019 World Conference on Lung Cancer.

September 10th 2019, 1:20am

IASLC World Conference on Lung Cancer

Anna F. Farago, MD, PhD, assistant professor of medicine, Harvard Medical School, discusses the updated activity of larotrectinib in NTRK fusion–positive lung cancer.

September 10th 2019, 12:20am

IASLC World Conference on Lung Cancer

Almost 70% of patients with previously treated RET-fusion–positive non–small cell lung cancer had objective responses to the RET inhibitor selpercatinib (LOXO-292), according to data from the phase I/II LIBRETTO-001 trial presented at the 2019 World Conference on Lung Cancer.

September 9th 2019, 9:44pm

IASLC World Conference on Lung Cancer

Patients with untreated extensive-stage small cell lung cancer had statistically significant improvement in overall survival when the PD-L1 inhibitor durvalumab (Imfinzi) was added to chemotherapy.

September 9th 2019, 1:53am

IASLC World Conference on Lung Cancer

The first-in-class AXL inhibitor bemcentinib (BGB324) demonstrated activity in combination with the PD-1 inhibitor pembrolizumab in patients with advanced non–small cell lung cancer who had no prior exposure to immunotherapy.

September 9th 2019, 1:35am

IASLC World Conference on Lung Cancer

Pasi A. Jänne, MD, PhD, discusses 3 studies of novel agents for targeting EGFR-mutant and HER2-positive lung cancers and the next steps in getting the research to cancer clinics.